在接受息治疗的人群中,便秘的管理
Jones Chen1, Phillip Good2, Claire Stokes3
1FRACGP, FAChPM, Palliative Care Specialist, Department of Cancer Services, Mater Adult Hospital, South Brisbane, Qld.
Australian journal of general practice
|August 4, 2025
概括
便秘显著影响着息护理患者. 有效的管理包括解决原因,非药物方法,以及推的松剂,如透剂和兴奋剂类型,特别是在处方阿片类药物时.
科学领域:
- 抚慰性护理医学 抚慰性护理医学
- 胃肠病学 胃肠病学
- 症状管理 症状管理
背景情况:
- 便秘是接受息治疗的患者普遍和令人痛苦的症状.
- 它显著降低了息护理机构中个人的生活质量.
研究的目的:
- 为评估和管理息治疗患者的便秘提供全面的概述.
- 引导医疗保健专业人员优化患者舒适性和护理.
主要方法:
- 审查当前文献和临床指导方针在息治疗中便秘管理.
- 讨论药理和非药理干预措施.
- 强调主动和个性化的治疗策略.
主要成果:
- 管理策略包括解决可逆原因,并采用非药理和药理干预措施.
- 在息治疗中,建议在便秘时使用奥斯莫斯和刺激性药.
- 在开始阿片类药物治疗时,预防性松剂的使用至关重要.
- 甲基纳勒是阿片类药物诱导的便秘的选择,在肠道阻塞中具有禁忌.
结论:
- 为了在息治疗中有效治疗便秘,必须采用多方面的方法.
- 及时和适当地使用药,特别是在阿片类药物使用时,可以改善患者的治疗结果.
- 个性化评估和治疗是提高生活质量的关键.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
336
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
336
Irritable Bowel Syndrome III: Medical and Nursing Management
303
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
303
Drugs Affecting GI Tract Motility: Other Laxatives
461
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
461
Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
305
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
305
Inflammatory Bowel Disease V: Surgical Management
213
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
213


